164 related articles for article (PubMed ID: 38527259)
21. Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
Luke JJ
Oncologist; 2019 Nov; 24(11):e1197-e1211. PubMed ID: 31064886
[TBL] [Abstract][Full Text] [Related]
22. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
Babacan NA; Eroglu Z
Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
[TBL] [Abstract][Full Text] [Related]
23. Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.
Sada I; Harada Y; Hiyama T; Mizukami M; Kan T; Kawai M; Kiuchi Y
Melanoma Res; 2023 Dec; 33(6):539-546. PubMed ID: 37788106
[TBL] [Abstract][Full Text] [Related]
24. Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.
De Ryck L; Delanghe S; Jacobs C; Fadaei S; Brochez L; Saerens M
Acta Clin Belg; 2023 Jun; 78(3):215-222. PubMed ID: 35996969
[TBL] [Abstract][Full Text] [Related]
25. Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma.
Ziogas DC; Konstantinou F; Bouros S; Gogas H
Expert Rev Anticancer Ther; 2020 Jan; 20(1):53-62. PubMed ID: 31903803
[No Abstract] [Full Text] [Related]
26. Combinatorial Approaches to the Treatment of Advanced Melanoma.
Munhoz RR; Postow MA
Hematol Oncol Clin North Am; 2021 Feb; 35(1):145-158. PubMed ID: 33759771
[TBL] [Abstract][Full Text] [Related]
27. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
[TBL] [Abstract][Full Text] [Related]
28. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
Schmitt AM; Dumas L; Larkin J
Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
31. [Immunotherapy for BRAF mutant metastatic melanoma.].
Rossi E
Recenti Prog Med; 2020 Dec; 111(12):48e-53e. PubMed ID: 33362182
[TBL] [Abstract][Full Text] [Related]
32. First-line immunotherapy versus targeted therapy in patients with
Pavlick AC; Zhao R; Lee CH; Ritchings C; Rao S
Future Oncol; 2021 Feb; 17(6):689-699. PubMed ID: 33084375
[No Abstract] [Full Text] [Related]
33. BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series.
Strelnikov J; Zhou A; Butt O; Ansstas M; Ansstas G
J Natl Compr Canc Netw; 2023 Aug; 21(10):991-999. PubMed ID: 37647938
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis.
Mincu RI; Mahabadi AA; Michel L; Mrotzek SM; Schadendorf D; Rassaf T; Totzeck M
JAMA Netw Open; 2019 Aug; 2(8):e198890. PubMed ID: 31397860
[TBL] [Abstract][Full Text] [Related]
35. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
36. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
Guardamagna M; Berciano-Guerrero MA; Villaescusa-González B; Perez-Ruiz E; Oliver J; Lavado-Valenzuela R; Rueda-Dominguez A; Barragán I; Queipo-Ortuño MI
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233289
[TBL] [Abstract][Full Text] [Related]
37. Cures with B-Raf inhibitors as single agents in metastatic B-Raf mutated melanoma: Curb your enthusiasm?
Dasanu CA
J Oncol Pharm Pract; 2021 Jan; 27(1):205-206. PubMed ID: 33241730
[TBL] [Abstract][Full Text] [Related]
38. Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
Awada G; Neyns B
Curr Opin Oncol; 2022 Mar; 34(2):115-122. PubMed ID: 35050937
[TBL] [Abstract][Full Text] [Related]
39. Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.
Berger M; Amini-Adlé M; Maucort-Boulch D; Robinson P; Thomas L; Dalle S; Courand PY
Cancer Med; 2020 Apr; 9(8):2611-2620. PubMed ID: 32056395
[TBL] [Abstract][Full Text] [Related]
40. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
